Asan Medical Center
Seoul, South Korea
NCT Number: NCT05656092
A multicenter, randomized, double-blind, active-controlled, phase III study to evaluate the efficacy and safety of HIP0612 in patients with gastric ulcer.
Looking for future studies?
Notify Me19 year–75 year
All sexes
Interventional
Phase 3
Seoul, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Test drug
Placebo drug
Reference drug
Placebo drug
Time frame: week 8
Including subjects endoscopically confirmed healing of gastric ulcer after 4 Weeks of treatment and complete the study
Time frame: week 4
Time frame: week 4, 8
Time frame: week 4, 8
Hanmi Pharmaceutical Company Limited
Industry
A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of HIP0612 in Patients With Gastric Ulcer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03553563
Digestive System Diseases, Duodenal Diseases
Bunkyō City, Japan
View Trial DetailsNCT06902818
Digestive System Diseases, Duodenal Diseases
Seoul, South Korea
View Trial DetailsNCT06642987
Digestive System Diseases, Duodenal Diseases
Siheung-si, South Korea
View Trial DetailsNCT05448001
Digestive System Diseases, Duodenal Diseases
Seoul, South Korea
View Trial Details